DOCSLIB.ORG

Angiotensin Converting Enzyme Inhibitors and Delayed Onset

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Angiotensin Converting Enzyme Inhibitors and Delayed Onset Angiotensin converting enzyme IN BRIEF • This paper highlights a possible serious cause of facial swelling presenting in a PRACTICE dental context. inhibitors and delayed onset, • Increases the reader’s knowledge of an important side-effect of a common medication. recurrent angioedema of the • Informs the reader of the causes and head and neck treatment of angioedema. Y. S. Wakefi eld,1 E. D. Theaker2 and M. N. Pemberton3 VERIFIABLE CPD PAPER Angiotensin converting enzyme (ACE) inhibitors are a commonly prescribed, effective medication in the treatment of hypertension and heart failure. Several side-effects of dental relevance can occur including angioedema of the lips, mouth and throat. This adverse effect is well reported and can be fatal, but it is not always recognised by clinicians, as the angioedema does not always have a clear relationship with the commencement of the medication. The cases of angioedema reported here all presented in a dental setting and highlight both the delayed onset and the chronic recurrent nature of ACE inhibitor induced angioedema. INTRODUCTION publication of NICE Clinical Guideline patient gave a 20 year history of recal- Angioedema describes a well-defi ned 34, which recommends that this group citrant lichen planus affecting both his non-pitting oedema of the subcutaneous of drugs should be the fi rst choice initial skin and mouth and was currently expe- tissues which can affect any area of the pharmacological intervention for hyper- riencing ulceration of his right buccal body but frequently presents as a tran- tension in patients under 55 years of age mucosa and lips, fi nding that topical sient swelling of the face and mucous (excluding patients of African and Car- steroids were of little help. The patient membranes.1-3 The swelling is usually of ibbean descent).10 Where angioedema also complained of frequent attacks acute onset and subsides after a couple secondary to ACE inhibitors occurs, in of spontaneously swollen lips occur- of days. The clinical picture can vary approximately 25% of patients the fi rst ring over the previous two years. These and ranges from mild localised symp- episode of angioedema will occur within attacks were of sudden onset with an toms to extensive upper airway obstruc- one month of the commencement of tak- increase in size over minutes subsid- tion, which can be fatal.4-6 Although ing the ACE inhibitor.11 However, it is ing over the next two days. The swell- allergy is sometimes the cause, many not uncommon for a patient to be taking ings were painless but of concern. The patients develop the problem for non- ACE inhibitors for many years before patient had sought the opinion of a der- allergic reasons and it is a well described any side-effects become apparent.4,5,12 matologist without success. He had a complication of angiotensin converting Because of this frequent lack of tempo- medical history of hypertension, hyper- enzyme (ACE) inhibitors.1-6 ral association between commencing the cholesterolaemia, angina, gout, oste- It is estimated that 35-40 million ACE inhibitor and angioedema occur- oarthritis, gastric ulcer, petit mal and patients worldwide are currently pre- ring, many clinicians are unaware of the impaired renal function. He had previ- scribed ACE inhibitors for treatment of causative relationship. ously suffered a myocardial infarction hypertension, heart failure and post- We here report fi ve cases of delayed and pulmonary embolism. In addition myocardial infarction.7 In this popu- onset angioedema that have presented a carcinoma had been excised from his lation group 0.1-0.2% are affected by to us in a dental setting over the last right ethmoid sinus. He had no known angioedema.8,9 The use of ACE inhibitors few years, to help raise awareness of allergies. The patient’s medication was in the UK is set to increase following the both this relationship and the chronic lamotrigine, clopidogrel, levetiracetam, recurrent nature of ACE inhibitor atenolol, co-proxamol, frusemide, prav- induced angioedema. astatin and ramipril. The patient had 1*Clinical Fellow, 2Lecturer, 3Consultant, Oral Medicine, been taking the ACE inhibitor ramipril University Dental Hospital of Manchester, Higher CASE REPORTS Cambridge Street, Manchester, M15 6FH 5 mg once a day for fi ve years. *Correspondence to: Mrs Yasha S. Wakefi eld Case 1 The patient was diagnosed with Email: yasha.wakefi [email protected] angioedema secondary to ACE inhibi- Refereed Paper An 81-year-old Caucasian male patient tors and ulcerative lichen planus. With Accepted 20 August 2008 DOI: 10.1038/sj.bdj.2008.982 was referred by his general dental prac- respect to the angioedema, his general ©British Dental Journal 2008; 205: 553-556 titioner (GDP) with a sore mouth. The medical practitioner (GMP) was contacted BRITISH DENTAL JOURNAL VOLUME 205 NO. 10 NOV 22 2008 553 © 2008 Macmillan Publishers Limited. All rights reserved. PRACTICE with a view to changing his ACE inhibi- tor to an alternative class of medication. For the treatment of his ulcerative lichen planus the patient was prescribed topical tacrolimus in orabase 0.1% and advised to apply sparingly to the affected areas of oral mucosa twice daily. At the review appointments the patient had not experienced any further episodes of angioedema following a change of his ramipril to an angiotensin II recep- tor antagonist. The patient also reported that his lichen planus had dramatically cleared up following use of tacrolimus. Case 2 A 64-year-old Caucasian male was referred by his GDP with recurrent epi- sodes of facial swelling. The patient gave a two year history of frequent recurrent transient swelling of the right side of Fig. 1 Swelling of upper lip due to angioedema his tongue, lips and face. The swellings were painless, appeared over 3-4 hrs each episode the patient had needed A diagnosis of angioedema secondary and lasted for 6-24 hrs. The patient had to attend an accident and emergency to ACE inhibitors was made and his GMP spent several thousand pounds on pri- department and was treated with ster- informed. After changing his lisinopril vate consultations with various medi- oids and antihistamines. The swelling to an angiotensin II receptor antago- cal specialists in an attempt to identify had decreased over a period of several nist no further episodes of angioedema the cause without success. He had no hours each time. The patient’s medical were reported. known allergies, although an allergic history consisted of angina, a previous cause to his swelling had been postu- myocardial infarction and bronchiecta- Case 5 lated. He had been prescribed an anti- sis. He had no known allergies. The An 86-year-old Afro-Caribbean male histamine for the episodes of swelling, patient was taking aspirin, lisinopril (an was referred by his GDP with a 21 month which had made very little difference. ACE inhibitor), bisoprolol, frusemide and history of intermittent episodes of swell- The patient’s medical history consisted isosorbide mononitrate. ing affecting his upper and lower lips. of hypertension, type II diabetes and The patient was diagnosed with These painless swellings occurred once mild asthma for which he was taking angioedema secondary to ACE inhibi- or twice each month, taking about an glibenclamide, aspirin, enalapril and a tors. The patient subsequently had his hour to develop fully and resolving salbutamol inhaler to use when needed. lisinopril changed to an angiotensin II slowly over the following two days. The The patient had been taking the ACE receptor antagonist and at his review patient’s medical history revealed that inhibitor enalapril 10 mg once a day for appointment reported no further he suffered from hypertension and had fi ve years. episodes of angioedema. undergone resection of an abdominal A diagnosis of angioedema second- tumour some fi ve years ago. He had no ary to ACE inhibitors was made. The Case 4 known allergies. His medication com- GMP was informed of the diagnosis, A 77-year-old Caucasian male was prised amlodipine, bendrofl umethiazide, and changed the patient’s enalapril to referred on an urgent basis by his GDP doxazosin, aspirin and enalapril. an angiotensin II receptor antagonist. At with a swollen upper lip (Fig. 1). He A diagnosis of angioedema second- review the patient reported a sustained gave a history of recurrent swelling ary to ACE inhibitors was made and the resolution in symptoms following his of his lips. The swellings were pain- patient’s GMP informed. The GMP was medication change. less, of rapid onset and usually resolved initially reluctant to change the patient’s within a day. The patient’s medical his- medication until the potential serious Case 3 tory consisted of asthma, hypertension consequences of upper aero-digestive A 78-year-old Caucasian male was and mitral valve prolapse for which he tract angioedema were emphasised in a referred by his GDP with a three month was taking bendrofl uazide, lisinopril further letter, following which the patient history of recurrent episodes of acute and a fl ixotide inhaler. He had been was commenced on the angiotensin II swellings of his tongue and throat. The taking the ACE inhibitor lisinopril 10 receptor antagonist losartan. At review swellings had a rapid onset and reached mg once daily for six years. He had no fi ve months later there had been no recur- a maximum in size after an hour. On known allergies. rence of the patient’s angioedema. 554 BRITISH DENTAL JOURNAL VOLUME 205 NO. 10 NOV 22 2008 © 2008 Macmillan Publishers Limited. All rights reserved. PRACTICE DISCUSSION of bradykinin, which would predispose and acquired angioedema are caused Since ACE inhibitors were fi rst intro- the patient to episodes of angioedema by C1 esterase inhibitor defi ciency or duced, the most common reported side- as the effect of the ACE inhibitor would dysfunction.20,21 Angioedema in these effect is a non-productive cough which is further raise the levels of bradykinin.
Load more

Recommended publications
  • A Randomized, Double-Blind, Placebo-Controlled Study
    medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20055715; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 1 Mo%on Sifnos: A randomized, double-blind, placebo-controlled study demonstra%ng the effec%veness of tradipitant in the treatment of mo%on sickness Vasilios M. Polymeropoulos*1, Mark É. Czeisler1#a, Mary M. Gibson1¶, Aus%n A. Anderson1¶, Jane Miglo1#b, Jingyuan Wang1, Changfu Xiao1, Christos M. Polymeropoulos1, Gunther Birznieks1, Mihael H. Polymeropoulos1 1 Vanda Pharmaceu%cals, Washington, District of Columbia, United States of America #a The Ins%tute for Breathing and Sleeping, Aus%n Health, Heidelberg, Victoria, Australia #b College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois, United States of America *Corresponding author Email: [email protected] (VMP) ¶These authors contributed equally to this work. NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2020.04.06.20055715; this version posted April 11, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license . 2 Abstract Background Novel therapies are needed for the treatment of mo%on sickness given the inadequate relief, and bothersome and dangerous adverse effects of currently approved therapies.
    [Show full text]
  • Adverse Drug Reactions Sample Chapter
    Sample copyright Pharmaceutical Press www.pharmpress.com 5 Drug-induced skin reactions Anne Lee and John Thomson Introduction Cutaneous drug eruptions are one of the most common types of adverse reaction to drug therapy, with an overall incidence rate of 2–3% in hos- pitalised patients.1–3 Almost any medicine can induce skin reactions, and certain drug classes, such as non-steroidal anti-inflammatory drugs (NSAIDs), antibiotics and antiepileptics, have drug eruption rates approaching 1–5%.4 Although most drug-related skin eruptions are not serious, some are severe and potentially life-threatening. Serious reac- tions include angio-oedema, erythroderma, Stevens–Johnson syndrome and toxic epidermal necrolysis. Drug eruptions can also occur as part of a spectrum of multiorgan involvement, for example in drug-induced sys- temic lupus erythematosus (see Chapter 11). As with other types of drug reaction, the pathogenesis of these eruptions may be either immunological or non-immunological. Healthcare professionals should carefully evalu- ate all drug-associated rashes. It is important that skin reactions are identified and documented in the patient record so that their recurrence can be avoided. This chapter describes common, serious and distinctive cutaneous reactions (excluding contact dermatitis, which may be due to any external irritant, including drugs and excipients), with guidance on diagnosis and management. A cutaneous drug reaction should be suspected in any patient who develops a rash during a course of drug therapy. The reaction may be due to any medicine the patient is currently taking or has recently been exposed to, including prescribed and over-the-counter medicines, herbal or homoeopathic preparations, vaccines or contrast media.
    [Show full text]
  • Plasma Contact System Activation Drives Anaphylaxis in Severe Mast Cell–Mediated Allergic Reactions
    Plasma contact system activation drives anaphylaxis in severe mast cell–mediated allergic reactions Anna Sala-Cunill, MD, PhD,a,b,c Jenny Bjorkqvist,€ MSc,c,d Riccardo Senter, MD,c,e Mar Guilarte, MD, PhD,a,b Victoria Cardona, MD, PhD,a,b Moises Labrador, MD, PhD,a,b Katrin F. Nickel, PhD,c,d,f Lynn Butler, PhD,c,d,f Olga Luengo, MD, PhD,a,b Parvin Kumar, MSc,c,d Linda Labberton, MSc,c,d Andy Long, PhD,f Antonio Di Gennaro, PhD,c,d Ellinor Kenne, PhD,c,d Anne Jams€ a,€ PhD,c,d Thorsten Krieger, MD,f Hartmut Schluter,€ PhD,f Tobias Fuchs, PhD,c,d,f Stefanie Flohr, PhD,g Ulrich Hassiepen, PhD,g Frederic Cumin, PhD,g Keith McCrae, MD,h Coen Maas, PhD,i Evi Stavrou, MD,j and Thomas Renne, MD, PhDc,d,f Barcelona, Spain, Stockholm, Sweden, Padua, Italy, Hamburg, Germany, Basel, Switzerland, Cleveland, Ohio, and Utrecht, The Netherlands Background: Anaphylaxis is an acute, potentially lethal, hypotension. Activated mast cells systemically released heparin, multisystem syndrome resulting from the sudden release of mast which provided a negatively charged surface for factor XII cell–derived mediators into the circulation. autoactivation. Activated factor XII generates plasma Objectives and Methods: We report here that a plasma protease kallikrein, which proteolyzes kininogen, leading to the cascade, the factor XII–driven contact system, critically liberation of bradykinin. We evaluated the contact system in contributes to the pathogenesis of anaphylaxis in both murine patients with anaphylaxis. In all 10 plasma samples models and human subjects. immunoblotting revealed activation of factor XII, plasma Results: Deficiency in or pharmacologic inhibition of factor XII, kallikrein, and kininogen during the acute phase of anaphylaxis plasma kallikrein, high-molecular-weight kininogen, or the but not at basal conditions or in healthy control subjects.
    [Show full text]
  • First Aid Management of Accidental Hypothermia and Cold Injuries - an Update of the Australian Resuscitation Council Guidelines
    First Aid Management of Accidental Hypothermia and Cold Injuries - an update of the Australian Resuscitation Council Guidelines Dr Rowena Christiansen ARC Representative Member Chair, Australian Ski Patrol Medical Advisory Committee All images are used solely for the purposes of education and information. Image credits may be found at the end of the presentation. 1 Affiliations • Medical Educator, University of Melbourne Medical • Chair, Associate Fellows Group, School Aerospace Medical Association • Director, Mars Society Australia • Board Member and SiG member, WADEM • Chair, Australian Ski Patrol Association Medical Advisory Committee • Inaugural Treasurer, Australasian Wilderness • Honorary Medical Officer, Mt Baw Baw Ski Patrol and Expedition Medicine Society (Victoria, Australia) • Member, Space Life Sciences Sub-Committee of • Representative Member, Australian Resuscitation Council the Australasian Society for Aerospace Medicine 2 Background • Australian Resuscitation Council (“ARC”) Guideline 9.3.3 “Hypothermia: First Aid Management” was published in February 2009; • Guideline 9.3.6 “Cold Injury” was published in March 2000; • A review of these Guidelines has been undertaken by the ARC First Aid task- force based on combination of a focused literature review and expert opinion (including from Australian surf life-saving and ski patrol organisations and the International Commission for Mountain Emergency Medicine (the Medical Commission of the International Commission on Alpine Rescue - “ICAR MEDCOM”); and • It is intended to publish the revised Guidelines as a jointly-badged product of the Australian and New Zealand Committee on Resuscitation (“ANZCOR”). 3 Defining the scope of the Guidelines • The scope of practice: • The ‘pre-hospital’ or ‘out-of-hospital’ setting. • Who does this guideline apply to? • This guideline applies to adult and child victims.
    [Show full text]
  • The Use of Radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor Deficiency
    Avances en Biomedicina ISSN: 2477-9369 ISSN: 2244-7881 [email protected] Universidad de los Andes Venezuela The use of radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor deficiency Lara de la Rosa, María del Pilar; Conde Alcañiz, Amparo; Moreno Ramírez, David; Illescas Vacas, Ana; Guardia Martínez, Pedro The use of radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor deficiency Avances en Biomedicina, vol. 7, no. 2, 2018 Universidad de los Andes, Venezuela Available in: https://www.redalyc.org/articulo.oa?id=331359393006 PDF generated from XML JATS4R by Redalyc Project academic non-profit, developed under the open access initiative Casos Clínicos e use of radiotherapy in Hereditary Angioedema Type 1- C1 Inhibitor deficiency Uso de radioterapia en Angioedema hereditario por déficit de C1 inhibidor tipo I María del Pilar Lara de la Rosa [email protected] University Hospital Virgen Macarena, España Amparo Conde Alcañiz University Hospital Virgen Macarena, España David Moreno Ramírez University Hospital Virgen Macarena, España Ana Illescas Vacas University Hospital Virgen Macarena, España Pedro Guardia Martínez University Hospital Virgen Macarena, España Avances en Biomedicina, vol. 7, no. 2, 2018 Universidad de los Andes, Venezuela Received: 27 February 2018 Accepted: 21 June 2018 Abstract: We present a clinical case of a 72 year old man with Hereditary Angioedema Type 1. It´s a rare, potentially fatal disease, especially due to causing episodes of Redalyc: https://www.redalyc.org/ laryngeal angioedema. He has a past medical history of lip squamous-cell skin cancer, articulo.oa?id=331359393006 which is currently relapsing, with lateral margins of the surgical resection affected requiring treatment with local radiotherapy.
    [Show full text]
  • Hereditary Angioedema: a Broad Review for Clinicians
    REVIEW ARTICLE Hereditary Angioedema A Broad Review for Clinicians Ugochukwu C. Nzeako, MD, MPH; Evangelo Frigas, MD; William J. Tremaine, MD ereditary angioedema (HAE) is an autosomal dominant disease that afflicts 1 in 10000 to 1 in 150000 persons; HAE has been reported in all races, and no sex predomi- nance has been found. It manifests as recurrent attacks of intense, massive, localized edema without concomitant pruritus, often resulting from one of several known trig- Hgers. However, attacks can occur in the absence of any identifiable initiating event. Historically, 2 types of HAE have been described. However, a variant, possibly X-linked, inherited angioedema has recently been described, and tentatively it has been named “type 3” HAE. Signs and symptoms are identical in all types of HAE. Skin and visceral organs may be involved by the typically massive local edema. The most commonly involved viscera are the respiratory and gastrointestinal sys- tems. Involvement of the upper airways can result in severe life-threatening symptoms, including the risk of asphyxiation, unless appropriate interventions are taken. Quantitative and functional analyses of C1 esterase inhibitor and complement components C4 and C1q should be performed when HAE is suspected. Acute exacerbations of the disease should be treated with intravenous purified C1 esterase inhibitor concentrate, where available. Intravenous administration of fresh frozen plasma is also useful in acute HAE; however, it occasionally exacerbates symptoms. Corti- costeroids, antihistamines, and epinephrine can be useful adjuncts but typically are not effica- cious in aborting acute attacks. Prophylactic management involves long-term use of attenuated androgens or antifibrinolytic agents.
    [Show full text]
  • Chapter 5 Biological Effects of Ionizing Radiation Page I
    CHAPTER 5 BIOLOGICAL EFFECTS OF IONIZING RADIATION PAGE I. Introduction ............................................................................................................................ 5-3 II. Mechanisms of Radiation Damage ........................................................................................ 5-3 A. Direct Action .............................................................................................................. 5-3 B. Indirect Action ........................................................................................................... 5-3 III. Determinants of Biological Effects ........................................................................................ 5-4 A. Rate of Absorption ..................................................................................................... 5-5 B. Area Exposed ............................................................................................................. 5-5 C. Variation in Species and Individual Sensitivity ......................................................... 5-5 D. Variation in Cell Sensitivity ....................................................................................... 5-5 IV. The Dose-Response Curve ..................................................................................................... 5-6 V. Pattern of Biological Effects .................................................................................................. 5-7 A. Prodromal Stage ........................................................................................................
    [Show full text]
  • Allergy, Hypersensitivity, Angioedema, and Anaphylaxis Episode Overview
    CrackCast Show Notes –Allergy and Anaphylaxis – October 2017 www.canadiem.org/crackcast Chapter 109 – Allergy, Hypersensitivity, Angioedema, and Anaphylaxis Episode Overview Key Points: 1. A history of sudden urticarial rash accompanied by respiratory difficulty, abdominal pain, or hypotension, strongly favors the diagnosis of anaphylaxis. 2. Epinephrine is the first-line treatment in patients with anaphylaxis: give it immediately. 3. There are no absolute contraindications to the use of epinephrine in the setting of anaphylaxis. 4. Antihistamines and corticosteroids are second- and third-line agents in the management of anaphylaxis and should not replace or precede epinephrine. 5. Consider prolonged observation or admission for patients who: a. Experience protracted anaphylaxis, hypotension, or airway involvement; b. Receive IV epinephrine or more than two doses of IM epinephrine; c. Or have poor outpatient social support. 6. Patients discharged after an anaphylactic event should be prescribed an EpiPen and instructed on its use. 7. Patients with refractory hypotension may require glucagon (receiving beta-blockage) or a continuous IV epinephrine infusion. 8. Non-histaminergic angioedema (non-allergic angioedema) does not typically respond to epinephrine and antihistamines. New drugs, including berinert, icatibant, ecallantide, and Ruconest have been approved for use in HAE. FFP has been used with varying success in HAE, ACID, and ACE inhibitor–induced angioedema. NOTE: ACID: acquired C1 esterase deficiency (ACED) Core Questions: 1. List the four types of Gell and Coombs classifications of immune reaction and give examples of each 2. List four etiologic agents causing anaphylaxis by immunologic mechanisms 3. List six mediators of anaphylaxis and their physiologic actions and clinical manifestations 4.
    [Show full text]
  • Acute Radiation Syndrome (ARS) – Treatment of the Reduced Host Defense
    International Journal of General Medicine Dovepress open access to scientific and medical research Open Access Full Text Article REVIEW Acute radiation syndrome (ARS) – treatment of the reduced host defense Lars Heslet1 Background: The current radiation threat from the Fukushima power plant accident has prompted Christiane Bay2 rethinking of the contingency plan for prophylaxis and treatment of the acute radiation syndrome Steen Nepper-Christensen3 (ARS). The well-documented effect of the growth factors (granulocyte colony-stimulating factor [G-CSF] and granulocyte-macrophage colony-stimulating factor [GM-CSF]) in acute radia- 1Serendex ApS, Gentofte; 2University of Copenhagen, tion injury has become standard treatment for ARS in the United States, based on the fact that Medical Faculty, Copenhagen; growth factors increase number and functions of both macrophages and granulocytes. 3 Department of Head and Neck Review of the current literature. Surgery, Otorhinolaryngology, Methods: Køge University Hospital, Køge, Results: The lungs have their own host defense system, based on alveolar macrophages. After Denmark radiation exposure to the lungs, resting macrophages can no longer be transformed, not even during systemic administration of growth factors because G-CSF/GM-CSF does not penetrate the alveoli. Under normal circumstances, locally-produced GM-CSF receptors transform resting macrophages into fully immunocompetent dendritic cells in the sealed-off pulmonary compartment. However, GM-CSF is not expressed in radiation injured tissue due to deferves- cence of the macrophages. In order to maintain the macrophage’s important role in host defense after radiation exposure, it is hypothesized that it is necessary to administer the drug exogenously in order to uphold the barrier against exogenous and endogenous infections and possibly prevent the potentially lethal systemic infection, which is the main cause of death in ARS.
    [Show full text]
  • Safety Assessment of Hydrofluorocarbon 152A As Used in Cosmetics
    Safety Assessment of Hydrofluorocarbon 152a as Used in Cosmetics Status: Tentative Report for Public Comment Release Date: October 7, 2016 Panel Meeting Date: April 10-11, 2017 All interested persons are provided 60 days from the above date to comment on this safety assessment and to identify additional published data that should be included or provide unpublished data which can be made public and included. Information may be submitted without identifying the source or the trade name of the cosmetic product containing the ingredient. All unpublished data submitted to CIR will be discussed in open meetings, will be available at the CIR office for review by any interested party and may be cited in a peer-reviewed scientific journal. Please submit data, comments, or requests to the CIR Director, Dr. Lillian J. Gill. The 2016 Cosmetic Ingredient Review Expert Panel members are: Chairman, Wilma F. Bergfeld, M.D., F.A.C.P.; Donald V. Belsito, M.D.; Ronald A. Hill, Ph.D.; Curtis D. Klaassen, Ph.D.; Daniel C. Liebler, Ph.D.; James G. Marks, Jr., M.D., Ronald C. Shank, Ph.D.; Thomas J. Slaga, Ph.D.; and Paul W. Snyder, D.V.M., Ph.D. The CIR Director is Lillian J. Gill, D.P.A. This report was prepared by Christina Burnett, Senior Scientific Analyst/Writer. Cosmetic Ingredient Review 1620 L Street NW, Suite 1200 ♢ Washington, DC 20036-4702 ♢ ph 202.331.0651 ♢ fax 202.331.0088 ♢ [email protected] ABSTRACT The Cosmetic Ingredient Review (CIR) Expert Panel (the Panel) reviewed the safety of Hydrofluorocarbon 152a, which functions as a propellant in personal care products.
    [Show full text]
  • Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor
    J Am Board Fam Pract: first published as 10.3122/jabfm.10.5.370 on 1 September 1997. Downloaded from BRIEF REPORTS Angioedema After Long-Term Use of an Angiotensin-Converting Enzyme Inhibitor Adriana]. Pavietic, MD Angioedema is an uncommon adverse effect of cyclobenzaprine, her angioedema was initially be­ angiotensin-converting enzyme (ACE) inhib­ lieved to be an allergic reaction to this drug, and itors. Its frequency ranges from 0.1 percent in pa­ it was discontinued. She was also given 125 mg of tients on captopril, lisinopril, and quinapril to 0.5 methylprednisolone intramuscularly. Her an­ percent in patients on benazepril. l Most cases are gioedema did not improve, and she returned to mild and occur within the first week of treat­ the clinic the following day. She was seen by an­ ment. 2-4 Recent reports indicate that late-onset other physician, who discontinued lisinopril, and angioedema might be more prevalent than ini­ her symptoms resolved within 24 hours. Mter her tially thought, and fatal cases have been de­ ACE inhibitor was discontinued, she experienced scribed.5-11 Many physicians are not familiar with more symptoms and an increased frequency of late-onset angioedema associated with ACE in­ palpitations, but she had no change in exercise hibitors, and a delayed diagnosis can have poten­ tolerance. A cardiologist was consulted, who pre­ tially serious consequences.5,8-II scribed the angiotensin II receptor antagonist losartan (initially at dosages of 25 mg/d and then Case Report 50 mg/d). The patient was advised to report any A 57-year-old African-American woman with symptoms or signs of angioedema immediately copyright.
    [Show full text]
  • Angioedema, a Life-Threatening Adverse Reaction to ACE-Inhibitors
    DOI: 10.2478/rjr-2019-0023 Romanian Journal of Rhinology, Volume 9, No. 36, October - December 2019 LITERATURE REVIEW Angioedema, a life-threatening adverse reaction to ACE-inhibitors Ramona Ungureanu1, Elena Madalan2 1ENT Department, “Dr. Victor Babes” Diagnostic and Treatment Center, Bucharest, Romania 2Allergology Department, “Dr. Victor Babes” Diagnostic and Treatment Center, Romania ABSTRACT Angioedema with life-threatening site is one of the most impressive and serious reasons for presenting to the ENT doctor. Among different causes (tumors, local infections, allergy reactions), an important cause is the side-effect of the angiotensin converting enzyme (ACE) inhibitors drugs. ACE-inhibitors-induced angioedema is described to be the most frequent form of bradykinin- mediated angioedema presented in emergency and also one of the most encountered drug-induced angioedema. The edema can involve one or more areas of the head and neck region, the most affected being the face, the lips, the tongue, followed by the larynx, when it may determine respiratory distress and even death. There are no specific diagnosis tests available and the positive diagnosis of ACE-inhibitors-induced angioedema is an exclusion diagnosis. The authors performed a review of the most important characteristics of the angioedema caused by ACE-inhibitors and present their experience emphasizing the diagnostic algorithm. KEYWORDS: angioedema, ACE-inhibitors, hereditary angioedema, bradykinin, histamine. INTRODUCTION with secondary local extravasation of plasma and tissue swelling5,6. Angioedema (AE) is a life-threatening condition Based on this pathomechanism, the classification presented as an asymmetric, localised, well-demar- of angioedema comprises three major types: 1). cated swelling1, located in the mucosal and submu- bradykinin-mediated – with either complement C1 cosal layers of the upper respiratory airways.
    [Show full text]